|

High-Energy Radiotherapy Treatment for Mesothelioma

ByHolly Zink
High-Energy Radiotherapy Treatment for Mesothelioma

A new Italian study found that accelerated hypofractionated radiotherapy was an effective and safe treatment for malignant pleural mesothelioma (MPM).

The patients in this study lived longer and had a lower risk of MPM coming back.

Treatment Approaches

MPM is a rare cancer that is difficult to treat. It develops from the thin layer of tissue that covers the lungs and chest wall. MPM is caused by exposure to asbestos.

Since MPM is a rare disease, the standard therapies are limited. The treatment plan for MPM depends on a few different factors. The stage of cancer, cell type of the cancer, and the health of the patient all affect what treatments will work the best.

The most common treatment approach uses more than one type of therapy. This can be surgery, radiation, or chemotherapy. When more than one of these therapies is used, it may be called multimodal therapy.

Understanding Radiotherapy

Accelerated hypofractionated radiotherapy is a type of cancer treatment that uses high-energy radiation to kill cancer cells. It is called “accelerated” because the treatment is given over a shorter period than traditional radiation therapy. It is also called “hypofractionated” because the treatment gives larger doses of radiation in each session.

This study looked at 20 patients with MPM who were treated with accelerated hypofractionated radiotherapy. The researchers aimed to measure how effective this therapy was in shrinking tumor size. They also wanted to find out if accelerated hypofractionated radiotherapy caused any side effects.

The patients in this study received chemotherapy before accelerated hypofractionated radiotherapy. The radiation treatment lasted for five days.

The researchers did not see any major side effects in patients after being treated with accelerated hypofractionated radiotherapy. Some patients ended up with fatigue, chest pain, or shortness of breath.

The one-year overall survival rate was 85% and the three-year overall survival rate was nearly 50%.

The researchers think that accelerated hypofractionated radiotherapy could be an important therapy after surgery in MPM patients.

Source

Parisi E, Arpa D, Ghigi G, et al. Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT). Cancers (Basel). 2023;15(4):1057. Published 2023 Feb 7. doi:10.3390/cancers15041057. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954648/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…